Main View
This view is used for searching all possible sources.
First Page Previous Page 1 2 Next Page Last Page
 
1
Botulinum neurotoxin type A-ABO (Dysport): clinical indications and practice guide.
2009-11-01

The key points to remember about abobotulinumtoxinA are as follows: BoNTA-ABO (abobotulinumtoxinA [Dysport]; Medicis Aesthetics, Scottsdale, AZ) and BoNTA-ONA (onabotulinumtoxin A [Botox Cosmetic]; Allergan, Irvine, CA) are both derivatives of botulinum toxin A produced from different strains of the bacterium Clostridium botulinum through proprietary manufacturing processes, ...

PubMed

2
Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study.
2001-12-01

Results from a dose-ranging study in a selected group of de novo patients with rotational cervical dystonia (CD) suggest that 500 units of Dysport (Clostridium botulinum toxin type A haemaglutinin complex) is the optimal starting dose. The present study aimed to confirm the efficacy and safety profile of this dose in a population of CD patients more representative of those ...

PubMed

3
Low-dose botulinum toxin-a treatment of cervical dystonia - a double-blind, randomized pilot study.
2002-01-01

The purpose of the study was to evaluate the clinical efficacy of low-dose botulinum toxin (BTX) treatment of cervical dystonia in a double-blind, randomized pilot study. Thirty-one patients with cervical dystonia and a minimum of 2 previous Dysport treatments received either a mean total target dose of 547 +/- 113 mouse units (MU) (group A, 500 MU ...

PubMed

4
Retrospective evaluation of the dose equivalence of Botox(�) and Dysport (�) in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story.
2011-06-28

Botox(�) and Dysport(�) are the preparations of botulinum neurotoxin most widely used for therapeutic purposes. Several studies have addressed the topic of the equivalency ratio (D/B ratio) to be used in clinical practice and whether a reliable value exists is still a matter of debate. To this purpose, we ideated a novel paradigm by retrospectively ...

PubMed

5
Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: a double-blind, randomized, dose-ranging study.
2008-10-07

Despite extensive clinical experience and published data regarding botulinum toxin, questions remain about the clinical substitution of one botulinum toxin formulation for another. In the case of Dysport and Botox, dose-equivalence ratios ranging from 1:1 to 6:1 (Dysport:Botox) have been advocated. This ...

PubMed

6
23 a�abo Aa

that sex is meant for procreation, and thus, the use of condoms promotes adultery and is immoral, even

E-print Network

7
Unilateral versus bilateral thyroarytenoid Botulinum toxin injections in adductor spasmodic dysphonia: a prospective study
2009-10-24

ObjectivesIn this preliminary prospective study, we compared unilateral and bilateral thyroarytenoid muscle injections of Botulinum toxin (Dysport) in 31 patients with adductor spasmodic dysphonia, who had undergone more than 5 consecutive Dysport injections (either unilateral or bilateral) and had completed 5 concomitant self-rated efficacy and ...

PubMed Central

8
[Use of botulinum neurotoxin therapy].
2011-07-01

Botulinum neurotoxins (BoNTs), produced by the gram-positive anaerobic bacterium Clostridium botulinum, act on motor nerve endings and induce muscle relaxation. BoNT type A and B are used as therapeutic agents. Several preparations of BoNT type A are commercially available; Botox�, Dysport�, and Xeomin� are popular. They differ in the manufacturing method used, for ...

PubMed

9
both

... OnabotulinumtoxinA (marketed as Botox/Botox Cosmetic), AbobotulinumtoxinA (marketed as Dysport) and RimabotulinumtoxinB (marketed as Myobloc) Information. ...

Center for Drug Evaluation (CDER)

10
Upper Facial Remodeling With Perlane-L and Dysport
2011-07-22

Mild to Moderate Temporal Atrophy; Moderate to Severe Glabellar Rhytids; Moderate to Severe Periorbital Rhytids

ClinicalTrials.gov

11
Botulinum toxin A (Dysport�): in dystonias and focal spasticity.
2011-05-28

Dysport�, a formulation of botulinum toxin A, blocks acetylcholine release at neuromuscular junctions causing denervation and temporary muscle paralysis. It is used to treat several medical conditions, including dystonias and focal spasticity. Subcutaneous Dysport� was effective in improving functional disability in adults with blepharospasm in a ...

PubMed

12
Update of Safety Review of OnabotulinumtoxinA (marketed as Botox ...

... toxin product in this class, Dysport, was approved on April 29, 2009 and included the Boxed Warning and REMS for the class of botulinum toxin products at the ...

Center for Drug Evaluation (CDER)

13
These highlights do not include all the information needed to use ...

... All vials, including expired vials, or equipment used with DYSPORT� should be disposed of carefully as is done with all medical waste. ...

Center for Drug Evaluation (CDER)

14
Post Marketing Surveillance Study of Dysport
2007-09-12

Blepharospasm; Hemifacial Spasm; Cervical Dystonia; Spasmodic Torticollis; Cerebral Palsy; Muscle Spasticity; Cerebrovascular Accident; Equinus Deformity; Facial Hyperdynamic Lines

ClinicalTrials.gov

15
Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.
2010-03-31

The aim of this study was to evaluate the efficacy and safety of intramuscular (IM) administration of botulinum toxin type A (Dysport((R)), Ipsen Biopharm Ltd.) for the treatment of cervical dystonia (CD) and the long-term safety and efficacy of repeated treatments. During the randomized, double-blind, placebo-controlled phase patients were randomized to 500 units ...

PubMed

16
T E C H N I C A L C O M M E N T Botulinum Toxin Injections as a Method for Chemically Denervating

toxin type A (commonly sold as Botox [Allergan] or Dysport [Ipsen]) is a zinc endopeptidase produced in mammalian systems (Simpson 1981; Schiavo et al. 1992; Brin 1997). In humans, Botox has been used- mercial type A toxins (Botox and Dysport) are compared (Pearce et al. 1995; Brin 1997). Furthermore

E-print Network

17
GENERAL INDEX. NOTll.-This index contains general references to the entire volume; more detailed indexes to two papers will be found at

, Pentagenia 27312741282 siccus, Chirotenetes , .. , , , .. ,......... 274,275 simulans, Ephemera 283.neous.. .. . . . .. .. .. . . . . .. . . . . .. . . . . . . .. . . . :aBo Mississippi River 271,279 diaphanus, Potamanthus , .. , , .. 287,288 Ephemera �276, :a77,278, 283 guttulata , 283,284 simulans 2831284,285 varia 383,284, 28S Ephemerida

E-print Network

18
Study design and methods of the BoTULS trial: a randomised controlled trial to evaluate the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.
2008-10-23

BACKGROUND: Following a stroke, 55-75% of patients experience upper limb problems in the longer term. Upper limb spasticity may cause pain, deformity and reduced function, affecting mood and independence. Botulinum toxin is used increasingly to treat focal spasticity, but its impact on upper limb function after stroke is unclear.The aim of this study is to evaluate the ...

PubMed

19
Study design and methods of the BoTULS trial: a randomised controlled trial to evaluate the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A
2008-10-23

BackgroundFollowing a stroke, 55�75% of patients experience upper limb problems in the longer term. Upper limb spasticity may cause pain, deformity and reduced function, affecting mood and independence. Botulinum toxin is used increasingly to treat focal spasticity, but its impact on upper limb function after stroke is unclear.The aim of this study is to evaluate the ...

PubMed Central

20
Periocular botulinum toxin.

Botulinum toxin type A (BOTOX, Dysport) has revolutionized treatment of wrinkles around the eyes. Since the first publications of its cosmetic benefit by Drs. Jean and Alastair Carruthers, hundreds of articles have been published about its cosmetic use. BOTOX holds U.S. Food and Drug Administration approval in the United States for treatment of glabellar lines. BOTOX is in ...

PubMed

First Page Previous Page 1 2 Next Page Last Page
 
First Page Previous Page 1 2 Next Page Last Page
 
21
Literature Highlight: Safety of Enteral Naloxone for the Reversal of Opiate-Induced Constipation in the

of Botox� 2 Treatments for Vitiligo 3-4 Inside this issue: DIS News College of Health Professions A (Botox�) was approved by the FDA on April 29, 2009. AbobotulinumtoxinA (Dysport�) is in- dicated� appears to be more ef- fective than Botox� for the treatment of cervical dystonia. It is also effective

E-print Network

22
Botulinum neurotoxin for management of intractable central leakage through a voice prosthesis in surgical voice restoration.
2006-07-24

Rehabilitation of voice and speech after total laryngectomy has become established practice in recent years. A voice prosthesis is placed within a surgically produced fistula between the trachea and upper oesophagus and acts as a one way valve, allowing passage of pulmonary air from the trachea into the oesophagus and preventing aspiration of food and fluid from the oesophagus into the trachea. ...

PubMed

23
UBC REPORTS T H E U N I V E R S I T Y O F B R I T I S H C O L U M B I A V O L U M E 5 2 | N U M B E R 1 2 | D E C E M B E R 7 , 2 0 0 6

as a cosmetic treatment, for example under the brand names Myobloc�, Botox� and Dysport�. In 2003, it is estimated that 2.27 million cosmetic procedures were performed18 , and by 2007 Botox� alone was worth $1

E-print Network

24
Myobloc.
2004-04-01

Myobloc is the currently available commercial formulation of type B botulinum toxin. Released in the United States in 2000, it is approved by the Food and Drug Administration for the treatment of cervical dystonia. The most commonly used botulinum toxins, the type A toxins (Botox and Dysport), affect the SNAP-25 protein, whereas the type B toxin (Myobloc) affects ...

PubMed

25
Botulinum toxin type A for the management of glabellar rhytids
2010-04-07

There is an increasing demand for minimally-invasive cosmetic procedures to arrest the aging process. Botulinum toxin type A injections are the most commonly used nonsurgical cosmetic procedures in the United States. There has been research spanning over two decades dedicated to safety, efficacy, dosing, and complications of botulinum toxin type A. There are now two Food and Drug Administration ...

PubMed Central

26
Clostridium botulinum: a bug with beauty and weapon.
2005-01-01

Clostridium botulinum, a Gram-positive, anaerobic spore-forming bacteria, is distinguished by its significant clinical applications as well as its potential to be used as bioterror agent. Growing cells secrete botulinum neurotoxin (BoNT), the most poisonous of all known poisons. While BoNT is the causative agent of deadly neuroparalytic botulism, it also serves as a remarkably ...

PubMed

27
Electronic and structural consequences of atomic-layer sequencing in the MBE growth of alkaline earth oxides and perovskites grown on silicon
2003-03-01

We use MBE to fabricate superlattices of the alkaline earth oxides AO (A=Ba, Sr, and Ca) and perovskites A'BO3 (B=Ti, Zr etc.) as single crystals on silicon. These structures can be expressed as (AO)n (A'BO_3)m where n is the number of alkaline earth oxide (001) planes (or monolayers) and m is the number of formula units or unit cells of perovskite. This fundamental unit can be grown epitaxially ...

NASA Astrophysics Data System (ADS)

28
Genetic history of the population of Puglia (southern Italy).
1995-04-01

Nine-hundred and twenty-two individuals belonging to the five provinces of Puglia were typed for nine erythrocyte genetic markers (ACP1, ADA, AK1, ESD, GLO1, PGD, PGM1, PGM2, and SODA). Genetic heterogeneity within Puglia was investigated on the basis of allele frequencies of the above mentioned markers plus ABO*A, ABO*B, ABO*O, and RH*D, by the (chi 2 ...

PubMed

29
The safety and tolerability of botulinum toxins for the treatment of cervical dystonia.
2005-03-01

The use of botulinum toxin to treat cervical dystonia (CD) has dramatically improved the quality of life of patients with this disabling, often painful disease. Two forms of type A toxin (BOTOX and Dysport) and one form of type B toxin (MyoBloc) are available in some parts of the world to treat patients with CD. The literature supports the efficacy of each in reducing the pain ...

PubMed

30
Sonoelastography contribution in cerebral palsy spasticity treatment assessment, preliminary report: a systematic review of the literature apropos of seven patients.
2010-12-01

This paper aims to present our experience of 7 cases of spastic children, using sonoelastography in assessing the muscle spasticity: the relaxed muscle structures appear mostly soft (green-yellow-red), while contracted or degenerated muscle fibers appear hard (blue). Using sonoelastographic findings we established the proper place for injecting the botulinum toxin (20 U/kg ...

PubMed

First Page Previous Page 1 2 Next Page Last Page